Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species
Latest Information Update: 18 Apr 2022
At a glance
- Drugs Piperacillin/tazobactam (Primary) ; Meropenem
- Indications Escherichia coli infections; Klebsiella infections
- Focus Therapeutic Use
- Acronyms MERINO
- 27 Oct 2020 Results of this post-hoc analysis assessing the association of piperacillin/tazobactam and meropenem minimum inhibitory concentration (MIC) and beta-lactam resistance genes with mortality published in the Clinical Infectious Diseases
- 11 Sep 2018 Primary endpoint (Mortality at 30 days) has not been met, according to the results published in the JAMA: the Journal of the American Medical Association
- 11 Sep 2018 Results published in the JAMA: the Journal of the American Medical Association